BCM
XFOR icon

Bridgeway Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Bridgeway Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-344
Closed -$100K – 1469
2018
Q3 		$100K Buy
344
+102
+42% +$43.3K ﹤0.01% 1382
2018
Q2 		$158K Sell
242
-28
-10% -$91.7K ﹤0.01% 1331
2018
Q1 		$1.11M Buy
+270
New +$786K 0.01% 809

Other funds holding XFOR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's XFOR Position: Q4 2018 in Review

Bridgeway Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2018, closing a stake of 344 shares — an estimated $100K sold.

Bridgeway Capital Management first reported a position in XFOR in Q1 2018 and held it in 3 quarters. The position peaked at $1.11M in Q1 2018. 36 funds tracked by Wall St. Rank hold XFOR as of Q4 2018.

  • Bridgeway Capital Management reported no remaining X4 Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Bridgeway Capital Management sold 344 X4 Pharmaceuticals shares in Q4 2018, an estimated $100K.
  • Bridgeway Capital Management first reported a position in X4 Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Bridgeway Capital Management's X4 Pharmaceuticals position peaked at $1.11M in Q1 2018.
  • 36 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2018.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.